Sanofi SA
SNW
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Stocks News & Analysis
stocks
Ask the analyst: Where does GYG stand following its US exit?
All roads lead back home for Guzman Y Gomez.
stocks
Chart of the Week: The long term headwinds facing copper shares
The key factors challenging the bull case for copper demand.
stocks
Australia’s oldest REIT undervalued
This REIT remains undervalued as trophy properties shine through.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,923.80 | 2.10 | 0.02% |
| CAC 40 | 8,337.29 | 66.70 | -0.79% |
| DAX 40 | 25,040.28 | 44.47 | 0.18% |
| Dow JONES (US) | 52,305.24 | 13.96 | -0.03% |
| FTSE 100 | 10,478.34 | 18.78 | -0.18% |
| HKSE | 23,027.49 | 146.47 | 0.64% |
| NASDAQ | 26,040.03 | 173.69 | -0.66% |
| Nikkei 225 | 68,758.97 | 1,715.99 | -2.43% |
| NZX 50 Index | 13,582.19 | 28.31 | -0.21% |
| S&P 500 | 7,483.23 | 16.13 | -0.22% |
| S&P/ASX 200 | 8,717.40 | 6.80 | 0.08% |
| SSE Composite Index | 4,054.69 | 57.76 | -1.40% |